I-Multicenter, i-1-year-long-world real-world study ibonisa ukusebenza kwe-semaglutide yokunciphisa umzimba

I-Semaglutide i-polypeptide eyenziwa ngoogqirha kunyango lwe-2 yeswekile.I-FDA ikuvumile ukusetyenziswa kwe-Novo Nordisk's Ozempic kunye ne-Rybelsus njengenaliti kanye ngeveki okanye njengethebhulethi, ngokulandelanayo.Isitofu se-semaglutide kanye ngeveki enegama le-brand Wegovy isandula kuvunywa njengonyango lokunciphisa umzimba.

Uphando olutsha oluvezwe kwi-European Congress on Obesity (ECO2023, Dublin, 17-20 May) lubonisa ukuba i-semaglutide yeziyobisi ezityebileyo iyasebenza ekulahlekeni kwesisindo kwi-multicenter, i-1-year-long-world real-world study.Uphononongo nguGqr Andres Acosta kunye noDkt Wissam Ghusn, i-Precision Medicine yeNkqubo yokuObesity kwiKliniki yaseMayo, eRochester, MN, eU.SA kunye noogxa.

I-Semaglutide, i-glucagon-like peptide-1 (GLP-1) i-receptor agonist, iyona mayeza asanda kwamkelwa yi-FDA echasene nokukhuluphala.Ibonise iziphumo ezibalulekileyo zokulahlekelwa kwesisindo kwiimvavanyo ezininzi zeklinikhi zexesha elide kunye nezifundo zehlabathi zangempela zexesha elifutshane.Nangona kunjalo, kuncinci okwaziwayo malunga nokuncipha kobunzima kunye neziphumo zeeparamitha zemetabolism kwizifundo zelizwe lokwenyani eliphakathi.Kulo pho nonongo, ababhali bavavanya iziphumo zokulahleka kwesisindo ezinxulumene ne-semaglutide kwizigulane ezinobunzima obukhulu kunye nokukhuluphala kunye nangaphandle kohlobo lwe-2 yeswekile (T2DM) kwi-1 unyaka wokulandela.

Benza i-retrospective, i-multicentre (Izibhedlele zeKliniki yaseMayo: eMinnesota, e-Arizona, naseFlorida) ukuqokelela idatha malunga nokusetyenziswa kwe-semaglutide kunyango lokukhuluphala.Baye baquka izigulane ezine-index mass body (BMI) ≥27 kg / m2 (ubunzima kunye nazo zonke iindidi ze-BMI eziphezulu) ezichazwe ngeveki ze-semaglutide ii-injection subcutaneous injections (i-doses 0.25, 0.5, 1, 1.7, 2, 2.4mg; nangona kunjalo uninzi lwalukhona. umthamo ophezulu we-2.4mg).Babengabandakanyi abaguli abasela amanye amayeza okutyeba ngokugqithiseleyo, abo banembali yotyando lokutyeba ngokugqithiseleyo, abo banomhlaza, nabo babekhulelwe.

Isiphelo esiphambili sasiyipesenti yokulahlekelwa kwesisindo somzimba (TBWL%) ngonyaka we-1.Amanqaku okugqibela asesekondari aquka umlinganiselo wezigulane ezifumana ≥5%, ≥10%, ≥15%, kunye ≥20% TBWL%, utshintsho kwiparameters ye-metabolic kunye ne-cardiovascular (uxinzelelo lwegazi, i-HbA1c [i-hemoglobin ye-glycated, umlinganiselo wokulawula iswekile yegazi], ukuzila i-glucose kunye namafutha egazi), i-TBWL% yezigulane kunye nangaphandle kwe-T2DM, kunye nokuphindaphindiweyo kwemiphumo emibi kunyaka wokuqala wonyango.

Izigulane ze-305 zizonke zifakwe kuhlalutyo (i-73% yabasetyhini, iminyaka yobudala be-49, i-92% emhlophe, ithetha i-BMI 41, i-26% kunye ne-T2DM).Iimpawu ezisisiseko kunye neenkcukacha zokutyelela zokulawula ubunzima zichazwe kwiThebhile 1 epheleleyo.Kulo lonke iqela, i-TBWL ephakathi% yayiyi-13.4% ngonyaka we-1 (kwizigulane ze-110 ezinedatha yesisindo kwi-1 ngonyaka).Izigulane ezine-T2DM zine-TBWL ephantsi ye-10.1% kwi-45 yezigulane ze-110 ezinedatha kwi-1 ngonyaka, xa kuthelekiswa nalabo abangenayo i-T2DM ye-16.7% ye-65 yezigulane ze-110 ezinedatha kwi-1 ngonyaka.

Ipesenti yezigulane ezilahlekelwe ngaphezu kwe-5% yobunzima bomzimba wabo ngu-82%, ngaphezu kwe-10% yayiyi-65%, ngaphezu kwe-15% yayiyi-41%, kwaye ngaphezu kwe-20% yayiyi-21% ngonyaka we-1.Unyango lwe-Semaglutide luye lwanciphisa kakhulu uxinzelelo lwegazi lwe-systolic kunye ne-diastolic nge-6.8 / 2.5 mmHg;i-cholesterol epheleleyo nge-10.2 mg / dL;I-LDL ye-5.1 mg / dL;kunye ne-triglycerides ye-17.6 mg / dL.Isiqingatha sezigulane siye safumana iziphumo ebezingalindelekanga ezinxulumene nokusetyenziswa kwamayeza (154/305) eyona nto ixeliweyo isicaphucaphu (38%) kunye norhudo (9%) (Figure 1D).Iziphumo ebezingalindelekanga bezincinci zingachaphazeli umgangatho wobomi kodwa kwiimeko ezili-16 ziye zakhokelela ekuyekisweni kwamayeza.

Ababhali baphetha ngokuthi: "I-Semaglutide idibaniswe nokulahlekelwa kwesisindo esibalulekileyo kunye nokuphuculwa kweeparameters ze-metabolic kunyaka we-1 kwi-multi-site ye-real-world study, ebonisa ukusebenza kwayo kunyango lokukhuluphala, kwizigulane ezine-T2DM kunye nangaphandle."

Iqela le-Mayo lilungiselela eminye imibhalo yesandla emalunga ne-semaglutide, kubandakanywa neziphumo zobunzima kwizigulane ezinesisindo sokuphindaphinda emva kokuhlinzwa kwe-bariatric;iziphumo zokulahlekelwa kwesisindo kwizigulane ezazimanye amayeza achasene nokutyeba ngaphambili xa kuthelekiswa nalawo ayengekho.